BioFire Diagnostics provides syndromic infectious disease diagnostics, focusing on rapid and accurate molecular testing.

BioFire Diagnostics

With more than 25 years of molecular experience, BioFire Diagnostics, LLC (now bioMérieux) sets the standard for molecular diagnostics through its pioneering advances in syndromic infectious disease testing. As BioMérieux’s Global Center of Excellence for Molecular Diagnostics, no other company has FDA-cleared and CE-IVD marked assays for more pathogens. BioFire Diagnostics has produced the easiest, fastest, and most comprehensive multiplex PCR testing available: the BioFire® FilmArray® System.

The FDA-cleared BioFire System panels test for viruses, bacteria, parasites, yeast, and antimicrobial resistance genes. Whether you’re trying to determine optimal therapy for a septic patient or pinpoint which respiratory pathogen is making a young child sick, the BioFire System can provide definitive answers—fast.

BioFire Diagnostics, LLC

The BioFire brand is evolving and there are some changes we’re excited to show you. bioMérieux, a global presence and world leader in infectious disease diagnostics, acquired BioFire in 2014 and it’s time to align our two companies. In January 2022, the BioFire product line will be folded into the bioMérieux product portfolio. As a company, it will simply be called bioMérieux. Read our newest blog post to see what the future holds for this amazing company. #WeArebioMerieux #NewBeginnings https://bit.ly/3o01mfV

COM:BIOFIREDX

BioFire Diagnostics

Financials Not Available